Effect of Yttrium-90 microsphere transarterial radioembolization for unresectable primary liver cancer：a Meta-analysis
10.3877/cma.j.issn.2095-3232.2014.06.006
- VernacularTitle:钇-90微球经动脉放疗栓塞治疗不可切除原发性肝癌疗效的Meta分析
- Author:
Muxing LI
1
;
Xufeng ZHANG
;
Jiwen CHENG
;
Ying ZHU
;
Wanli WANG
;
Jian DONG
;
Zhida LONG
;
Yi LYU
Author Information
1. 710061西安交通大学医学院第一附属医院肝胆外科西安交通大学先进外科技术与工程研究所
- Keywords:
Carcinoma,hepatocellular;
Yttrium,radioisotopes;
Radiotherapy;
Chemoembolization,therapeutic;
Meta-analysis
- From:
Chinese Journal of Hepatic Surgery（Electronic Edition）
2014;(6):26-30
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo assess the effect of transarterial radioembolization (TARE) using Yttrium-90 microsphere for unresectable primary liver cancer (PLC).MethodsLiterature from January 2009 to December 2013 were searched in the Medline, Web of Science, Cochrane Controlled Trial Register (CENTRAL) and EMBASE databases with the search terms mainly including: radioembolization, transarterial radioembolization, TARE, selective internal radiation therapy, SIRT, Yttrium-90, 90Y, chemoembolization, transarterial chemoembolization (TACE), hepatocellular carcinoma, HCC, liver cancer, liver tumor, liver neoplasm and with the assistance of manual searching. Data of the included literature were merged and the patients were divided into TARE group and TACE group according to the different treatments. The data of tumor therapeutic response and 1-, 2-, 3-year survival rates were collected. Literature heterogeneity inspection was conducted byQ test. Publication bias was tested by drawing funnel plot and linear regression model.ResultsFive articles were included after screening with the quality of medium to high. There were totally 591 cases with 292 in TARE group and 299 in TACE group. Meta-analysis was conducted using fixed effect model. Tumor therapeutic response was observed better in TARE group, compared with that in TACE group (RR=1.50,P<0.05). The 2-, 3-year survival rates in TARE group were signiifcantly higher than those in TACE group (RR=1.56, 2.04;P<0.05).ConclusionsCompared with TACE, TARE can obviously improve the tumor therapeutic response rate and long-term survival rate of patients with unresectable PLC.
